Format
Sort by
Items per page

Send to

Choose Destination

Best matches for oncolytic poliovirus:

Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. Brown MC et al. Curr Opin Virol. (2015)

Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus. Brown MC et al. Discov Med. (2015)

Oncolytic polio virotherapy of cancer. Brown MC et al. Cancer. (2014)

Search results

Items: 1 to 20 of 52

1.

Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.

Walton RW, Brown MC, Sacco MT, Gromeier M.

J Virol. 2018 Jul 11. pii: JVI.00879-18. doi: 10.1128/JVI.00879-18. [Epub ahead of print]

PMID:
29997212
2.

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD.

N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26.

3.

Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma.

Thompson EM, Brown M, Dobrikova E, Ramaswamy V, Taylor MD, McLendon R, Sanks J, Chandramohan V, Bigner D, Gromeier M.

J Neuropathol Exp Neurol. 2018 Aug 1;77(8):696-702. doi: 10.1093/jnen/nly045.

PMID:
29878245
4.

Recombinant Poliovirus for Cancer Immunotherapy.

Gromeier M, Nair SK.

Annu Rev Med. 2018 Jan 29;69:289-299. doi: 10.1146/annurev-med-050715-104655.

5.

Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.

Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK.

Sci Transl Med. 2017 Sep 20;9(408). pii: eaan4220. doi: 10.1126/scitranslmed.aan4220.

6.

Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.

Chandramohan V, Bryant JD, Piao H, Keir ST, Lipp ES, Lefaivre M, Perkinson K, Bigner DD, Gromeier M, McLendon RE.

Arch Pathol Lab Med. 2017 Dec;141(12):1697-1704. doi: 10.5858/arpa.2016-0580-OA. Epub 2017 Aug 22.

PMID:
28829151
7.

Oncolytic Virotherapy for the Treatment of Malignant Glioma.

Foreman PM, Friedman GK, Cassady KA, Markert JM.

Neurotherapeutics. 2017 Apr;14(2):333-344. doi: 10.1007/s13311-017-0516-0. Review.

8.

Measles Virus Enters Breast and Colon Cancer Cell Lines through a PVRL4-Mediated Macropinocytosis Pathway.

Delpeut S, Sisson G, Black KM, Richardson CD.

J Virol. 2017 Apr 28;91(10). pii: e02191-16. doi: 10.1128/JVI.02191-16. Print 2017 May 15.

9.

The Practical Consideration of Poliovirus as an Oncolytic Virotherapy.

Denniston E, Crewdson H, Rucinsky N, Stegman A, Remenar D, Moio K, Clark B, Higginbotham A, Keffer R, Brammer S, Horzempa J.

Am J Virol. 2016;5(1):1-7. Epub 2016 Mar 3.

10.

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.

Affronti ML, Woodring S, Peters KB, Herndon JE 2nd, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS.

Ther Clin Risk Manag. 2016 Dec 23;13:33-40. doi: 10.2147/TCRM.S122480. eCollection 2017.

11.

Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.

Holl EK, Brown MC, Boczkowski D, McNamara MA, George DJ, Bigner DD, Gromeier M, Nair SK.

Oncotarget. 2016 Nov 29;7(48):79828-79841. doi: 10.18632/oncotarget.12975.

12.

Sensitivity of C6 Glioma Cells Carrying the Human Poliovirus Receptor to Oncolytic Polioviruses.

Sosnovtseva AO, Lipatova AV, Grinenko NF, Baklaushev VP, Chumakov PM, Chekhonin VP.

Bull Exp Biol Med. 2016 Oct;161(6):821-825. Epub 2016 Oct 26.

PMID:
27783287
13.

MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors.

Geekiyanage H, Galanis E.

Mol Oncol. 2016 Nov;10(9):1387-1403. doi: 10.1016/j.molonc.2016.07.007. Epub 2016 Jul 28.

14.

Development of new therapy for canine mammary cancer with recombinant measles virus.

Shoji K, Yoneda M, Fujiyuki T, Amagai Y, Tanaka A, Matsuda A, Ogihara K, Naya Y, Ikeda F, Matsuda H, Sato H, Kai C.

Mol Ther Oncolytics. 2016 Jan 13;3:15022. doi: 10.1038/mto.2015.22. eCollection 2016.

15.

Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells.

Amagai Y, Fujiyuki T, Yoneda M, Shoji K, Furukawa Y, Sato H, Kai C.

Sci Rep. 2016 Apr 19;6:24572. doi: 10.1038/srep24572.

16.

Therapeutic Use of Native and Recombinant Enteroviruses.

Ylä-Pelto J, Tripathi L, Susi P.

Viruses. 2016 Feb 23;8(3):57. doi: 10.3390/v8030057. Review.

17.

EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.

Saha D, Ahmed SS, Rabkin SD.

Drugs Future. 2015;40(11):739-749.

18.
19.

Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus.

Brown MC, Gromeier M.

Curr Opin Virol. 2015 Aug;13:81-5. doi: 10.1016/j.coviro.2015.05.007. Epub 2015 Jun 12. Review.

20.

An Enterovirus-Like RNA Construct for Colon Cancer Suicide Gene Therapy.

Rasekhian M, Teimoori-Toolabi L, Amini S, Azadmanesh K.

Iran Biomed J. 2015;19(3):124-32. Epub 2015 Jun 6.

Supplemental Content

Loading ...
Support Center